louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05409053: Kirschner Wires Fixation Versus Cannulated Screws Internal Fixation for Displaced Lateral Condyle Humeral Fracture in Children
Official title: Open Reduction and Kirschner Wires Fixation Versus Cannulated Screws Internal Fixation for Displaced Lateral Condyle Humeral Fracture in Children. Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lateral Condyle Humerus Fracture in Children
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 20
Sex: ALL
Minimum age (years): 2
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Lateral condyle fracture of the distal humerus is the second most common injury around the elbow and accounts for 20% of all the elbow fractures in children.The average age for the fracture involving the lateral condyle is around six years.

There are different treatment options of the lateral condyle fractures include

* non-operative management with plaster cast immobilization for undisplaced or minimally displaced fractures.
* Whereas the fractures displaced \>2 mm need operative management. The objective of treatment in the displaced fracture is to obtain and maintain the articular congruity.

In the operative management, the reduction technique includes open or closed methods.


Eligibility criteria: Inclusion Criteria:

* Children up to 14 years.
* closed lateral condylar fracture.
* displacement more than 2mm .
* fracture Less than two weeks of injury.

Exclusion Criteria:

* Patients with open fractures.
* otherassociated injury in the same elbow .
* elbow with preexisting anatomical deformity .

Primary outcomes:
measure: Time of union
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
citation: Franks D, Shatrov J, Symes M, Little DG, Cheng TL. Cannulated screw versus Kirschner-wire fixation for Milch II lateral condyle fractures in a paediatric sawbone model: a biomechanical comparison. J Child Orthop. 2018 Feb 1;12(1):29-35. doi: 10.1302/1863-2548.12.170090.
citation: Justus C, Haruno LS, Riordan MK, Wilsford L, Smith T, Antekeier S, McKay SD. Closed and Open Reduction of Displaced Pediatric Lateral Condyle Humeral Fractures, a Study of Short-Term Complications and Postoperative Protocols. Iowa Orthop J. 2017;37:163-169.
citation: Cardona JI, Riddle E, Kumar SJ. Displaced fractures of the lateral humeral condyle: criteria for implant removal. J Pediatr Orthop. 2002 Mar-Apr;22(2):194-7.
citation: Baharuddin M, Sharaf I. Screw osteosynthesis in the treatment of fracture lateral humeral condyle in children. Med J Malaysia. 2001 Dec;56 Suppl D:45-7.
Clinical trial NCT03479853: Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE
Official title: Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ocular Rosacea
Keratoconjunctivitis
Meibomian Gland Dysfunction
Keywords: Ocular Rosacea
Keratoconjunctivitis
Meibomian Gland
Interferometry
Child
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2018-03-27
Enrollment: 102
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children aged between 2 and 16 : Cases, suffering from ocular or oculo-cutaneous rosacea and Witnesses without any present or past palpebral or meibomian disease

Brief summary: The aim of this study is to describe the clinical, meibographic and interferometric manifestations of phlyctenular keratitis in children.

Detailed description: The investigators are conducting a monocentric, transversal, epidemiologic study. 100 patients should be included: 50 children suffering from ocular rosacea, and 50 children with no palpebral or Meibomian disease. Witnesses will be matched on the age of the cases.

Patient and controls will undergo a classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, the child will go through a meibographic and interferometric evaluation of his two inferior eyelids. This evaluation is made by an optometrist with the Lipiview device, and lasts a few minutes.

Eligibility criteria: Inclusion Criteria:

* Recruited from a specialized ophthalmologic consultation Rothschild Ophthalmologic Foundation, Paris, France.
* Cases : suffering from ocular or oculo-cutaneous rosacea
* Witnesses : without any present or past palpebral or meibomian disease

Exclusion Criteria:

* Unable to achieve the meibographic and interferometric examination (Lipiview)

Primary outcomes:
measure: Clinical severity
timeFrame: Day of inclusion
measure: Meibographic severity
timeFrame: Day of inclusion
measure: Interferometric severity
timeFrame: Day of inclusion
measure: Number of abortive blinks
timeFrame: Day of inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique A. de Rothschild
Study officials:
affiliation: Fondation Ophtalmologique A. de Rothschild
name: Serge DOAN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01649453: A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test
Official title: A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Neoplasm Metastasis
Keywords: Neoplasms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Lead sponsor: Cedar Associates LLC
Sponsor class: OTHER
Collaborators: name: Pathwork Diagnostics
First posted: 2012-07-25
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community and academic clinics

Brief summary: The study prospectively assesses the change in cancer-specific clinical decisions and outcomes before and after physicians received results from the Pathwork® Tissue of Origin (TOO) Test for patients whose primary site of cancer origin is uncertain.


Eligibility criteria: Inclusion Criteria:

* their physician ordered or intends to order a Pathwork® TOO Test between May 2012 and December 2013
* the patient is ≥ 18 years of age
* the patient has given informed consent (online or verbal)
* the patient is able to understand English.

Primary outcomes:
measure: Survival
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Menlo Park
country: United States
facility: Cedar Associates LLC
state: California
Study officials:
affiliation: Cedar Associates LLC
name: John Hornberger, MD MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04890353: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
Official title: Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Acute Ischemic Stroke
Keywords: Dimethyl Fumarate
acute ischemic stroke
immune modulation
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
First posted: 2021-05-18
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke.


Eligibility criteria: Inclusion Criteria:

1. \>18 y of age;
2. acute onset of focal neurological deficit consistent with acute ischemic stroke;
3. measurable neurological deficit (NIHSS ≥ 5);
4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (MRA) and Diffusion-Weighted Imaging(DWI);
5. onset of symptom to admission more than 4.5 h and less than 72 h. Patients who arrived within 0-4.5 h poststroke were treated with other medications according to the best accepted medical treatment guidelines.

Exclusion Criteria:

1. Other diseases of the central nervous system
2. There has been neurological disability in the past (mRS score\>2)
3. Difficulty swallowing
4. Arrhythmia, atrioventricular block
5. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs
6. Macular edema
7. MRA shows vertebral basilar artery obstruction
8. Hemorrhagic stroke
9. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product
10. Pregnant and lactating women

Primary outcomes:
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 7
measure: Lesion Volume
timeFrame: day 7
Secondary outcomes:
measure: The Modified Rankin Scale (mRS)
timeFrame: day1
measure: The Modified Rankin Scale (mRS)
timeFrame: day3
measure: The Modified Rankin Scale (mRS)
timeFrame: day7
measure: The Modified Rankin Scale (mRS)
timeFrame: day14
measure: The Modified Rankin Scale (mRS)
timeFrame: day90
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 1
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 3
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 14
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 90
measure: Lesion Volume
timeFrame: day 1
measure: Lesion Volume
timeFrame: day 3
measure: Lesion Volume
timeFrame: day 90
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital, Capital Medical University
Study officials:
References:
Clinical trial NCT05108753: Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China
Official title: Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China: Retrospective Study of the First Twenty-five Cases in Seven High-volume Centers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rectal Cancer
Lead sponsor: Shanghai Minimally Invasive Surgery Center
Sponsor class: OTHER
First posted: 2021-11-05
Enrollment: 175
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: rectal cancer

Brief summary: Transanal total mesorectal excision (TaTME) is an alternative for mid-low rectal cancer. In China, this procedure has been performed in high-volume centers with structured training curriculums. This study aimed to evaluate the short-term outcomes during the initial implementation of the TaTME procedure in high-volume centers who followed structured training curriculums in China.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 75 years
* American Society of Anesthesiologists (ASA) score I to III
* A biopsy proven histological diagnosis of rectal carcinoma
* Undergoing transanal total mesorectal excision

Exclusion Criteria:

* Pregnant or lactating women
* Synchronous rectal carcinoma
* History of colorectal cancer or other malignant tumors
* Clinical evidence of metastasis
* Emergency procedure

Primary outcomes:
measure: incidence of anastomotic leakage
timeFrame: thirty days after surgery
Secondary outcomes:
measure: incidence of Defecation disorders
timeFrame: 6 months after surgery
measure: incidence of positive distal resection margin
timeFrame: 30 days after surgery
measure: incidence of positivecircumferential resection margin
timeFrame: 30 days after surgery
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Minimally Invasive Surgery Center
Study officials:
References:
Clinical trial NCT00289653: Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation
Official title: Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nicotine Dependence
Keywords: nicotine dependence,
transdermal nicotine patch,
smoking while receiving nicotine replacement,
comorbidities
Lead sponsor: Centre for Addiction and Mental Health
Sponsor class: OTHER
First posted: 2006-02-10
Enrollment: 23
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Smoking while on nicotine patches will help subjects to reduce their expired carbon monoxide levels from the levels they were before they started using the patch. Subjects will also decrease their daily consumption of cigarettes.

Detailed description: Subjects who smoke while on an individually dosed tNRT will reduce their expired carbon monoxide levels from pre- to post-treatment conditions. They will also decrease their daily consumption of cigarettes.

Eligibility criteria: Inclusion Criteria:

* at least 19 years of age
* male or female
* have intention to quit smoking within the next 6 months
* smoke 10 or more cigarettes per day

Exclusion Criteria:

* Pregnant or not using an adequate enough method of birth control to ensure that they are not at risk of becoming pregnant
* breastfeeding
* have any generalized skin disorders
* are in an immediate post-myocardial infarction period or have life-threatening arrhythmias, have severe or worsening angina pectoris or have had a recent cerebral vascular accident
* are using additional nicotine replacement therapies or any other smoking cessation pharmacotherapy
* any clinically significant ECG abnormalities
* any known hypersensitivity to components of the transdermal system

Primary outcomes:
measure: Carbon Monoxide Levels
timeFrame: measured at week 10
Secondary outcomes:
measure: Smoking Cessation
timeFrame: Week 10
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Centre for Addiction and Mental Health
state: Ontario
Study officials:
affiliation: Centre for Addiction and Mental Health
name: Peter L. Selby, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Selby P, Andriash K, Zawertailo L, Persad D, Zack M, Busto UE. Escalating doses of transdermal nicotine in heavy smokers: effects on smoking behavior and craving. J Clin Psychopharmacol. 2013 Oct;33(5):667-74. doi: 10.1097/JCP.0b013e31829a829d.
Clinical trial NCT01785953: Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia
Official title: CONVENTIONAL AND EXPERIMENTAL CHEMOTHERAPY WITH ALLOGENEIC TRANSPLANT IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKAEMIA
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myeloid Leukemia
Lead sponsor: Azienda Ospedaliera San Giovanni Battista
Sponsor class: OTHER
First posted: 2013-02-07
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute myeloid leukemia patients

Brief summary: The purpose of this study is evaluate patients with acute myeloid leukemia (\<=66 years), treated with conventional and experimental chemotherapy following allogeneic transplantation. THis patients have been enrolled from 2000 to 2011 at the Division of Hematology, Molinette University Hospital. The purpose of data collection is to assess, with retrospective analysis, the clinical outcome divided by risk class and evaluated in patients who achieve complete remission after induction therapy and consolidation.


Eligibility criteria: Patients with acute myeloid leukemia (\<=66 years), treated with conventional and experimental chemotherapy following allogeneic transplantation. THis patients have been enrolled from 2000 to 2011 at the Division of Hematology, Molinette University Hospital.

Primary outcomes:
measure: Overall survival
timeFrame: 1 year
measure: Event-free survival
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Torino
country: Italy
facility: Città della Salute e della Scienza di Torino
Study officials:
affiliation: Divisione di Ematologia-Città della Salute e della Scienza di Torino
name: Benedetto Bruno, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03650153: Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
Official title: Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: Princess Al-Johara Al-Ibrahim Cancer Research Center
Sponsor class: OTHER
First posted: 2018-08-28
Enrollment: 165
Sex: MALE
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This prospective study of comparing between Transrectal and transperineal prostate MRI targeted biopsy to provide evidence for clinicians to select the appropriate biopsy approach under different conditions.

Detailed description: This prospective study of comparing transperineal (TP) prostate MRI targeted biopsy with transrectal (TR) prostate MRI targeted biopsy was aimed to provide evidence for clinicians to select the appropriate biopsy approach under different conditions. TP (n = 75) and TR (n = 75) will be performed randomly for 150 patients who are suspicious of prostate cancer (PCa). The cancer detection rate (CDR), complication rate, visual analog scale (VAS) score, most painful procedure, number of repeated biopsy and additional anesthesia, and operating time (starting from lying down on the operating table to getting up) will be recorded.

Eligibility criteria: Inclusion Criteria:

* prostate-specific antigen \> 4ng/ml
* Palpation is positive

Exclusion Criteria:

* older than 80y
* prostate-specific antigen \> 100 ng/ml

Primary outcomes:
measure: the rate of positive detections
timeFrame: 1 year
Secondary outcomes:
measure: the incidence rate of each complication
timeFrame: 1 year
Other outcomes:
measure: Pain level assessed by visual analogue scale (VAS)
timeFrame: 1 year
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Khalid University Hospital
Study officials:
affiliation: Surgery Department and Cancer Research Chair, College of Medicine, King Saud University, Saudi Arabia
name: danny M Rabah, FRCS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03687853: Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery
Official title: Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pancreatic Ductal Adenocarcinoma
Who Have High CTCs Count in Portal Venous Blood
Liver Metastases
Keywords: Pancreatic ductal adenocarcinoma
arterial infusion chemotherapy
liver metastases
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2018-09-27
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Pancreatic cancer patients who received hepatic arterial perfusion chemotherapy after operation
Primary purpose: PREVENTION

Brief summary: Clinical results on intra-arterial adjuvant chemotherapy for prevention

of liver metastasis following curative resection of pancreatic cancer

Detailed description: In this study, the investigator try to select 80 patients who received radical surgery for pancreatic cancer, whose circulating tumor cells(CTCs) count then performed on intraoperative portal venous blood to predict postoperative liver metastasis and were divided into two groups. for those who have high CTCs count may have more chance for the occurrence of postoperative liver metastasis was applied hepatic arterial perfusion chemotherapy with minimal dynamic randomization. The aim is to evaluate the feasibility of hepatic arterial infusion chemotherapy for the prevention of postoperative liver metastasis and improvement of prognosis of pancreatic cancer, so as to further improve postoperative management of pancreatic cancer

Eligibility criteria: Inclusion Criteria:

* pancreatic cancer patients who received the radical operation

Exclusion Criteria:

* who accepted chemotherapy before operation or who cannot or do not will to accepted enrolled into this study

Primary outcomes:
measure: Death
timeFrame: up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of General Surgery,Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: dianrong xiu, doctor
role: STUDY_CHAIR
References: